Summary
Benzedrone, also known as 4-MBC, is a synthetic designer drug that emerged around 2010 and has been detected as a component in various “bath salt” blends marketed for recreational purposes.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 1225617-75-3 |
|---|---|
| PubChem CID | 57493771 |
| ChemSpider | 25630094 |
| UNII | V6Z5G5VE87 |
| Chemical and physical data | |
| Formula | C17H19NO |
| Molar mass | 253.345 g·mol−1 |
FAQ
1. What is Benzedrone (4-MBC)?
Benzedrone, commonly called 4-MBC, is a synthetic designer drug known for its stimulant properties. It belongs to the substituted cathinone class of chemicals and is often associated with recreational drug use.
2. Is Benzedrone legal?
The legal status of Benzedrine varies from one region to another. It may be classified as a controlled substance in some areas, while it remains legal or unregulated in others. Check your local and national drug laws and regulations to determine their legality.
3. How is Benzedrone typically consumed?
Benzedrone is often found as a white or off-white powder and is usually ingested by oral consumption, insufflation (snorting), or, in some cases, vaporization. It is important to note that using any illicit substances can pose serious health risks.
4. What are the effects of Benzedrone?
Benzedrone is primarily known for its stimulant effects, including increased energy, alertness, and euphoria. However, it may also lead to negative side effects, such as anxiety, restlessness, and potential health risks, especially when used in high doses.
5. Are there health risks associated with Benzedrone use?
Yes, the use of Benzedrine can pose several health risks. Users may experience increased heart rate, elevated blood pressure, and potential psychiatric side effects, including anxiety and paranoia. Prolonged or high-dose use can exacerbate these risks and may lead to more severe consequences.
6. Can Benzedrone be addictive?
Like many other stimulants, Benzedrone has the potential for addiction and dependence. Frequent or heavy use can lead to physical and psychological dependence, making quitting difficult.
7. How can I reduce the risks associated with Benzedrone use?
The safest approach is to avoid using Benzedrone altogether. If you choose to use it, be aware of the potential risks, use it in moderation, and never combine it with other substances. Ensure you are well-informed about harm reduction strategies and have a support system.
8. Are there any treatment options for Benzedrine addiction?
Treatment options for Benzedrone addiction may include counseling, therapy, and support groups. If you or someone you know is struggling with Benzedrine addiction, it is essential to seek professional help and support to address the problem.
9. Can you provide information on drug testing for Benzedrone?
Standard drug tests, like urine tests, are not typically designed to detect Benzedrone. However, specialized tests may be able to identify it in a person’s system. It’s essential to be aware of the drug testing policies in your area, especially if you face potential legal consequences.
10. Where can I find more information about Benzedrone?
For the most up-to-date and accurate information about Benzedrone, consult with medical professionals, addiction support organizations, or drug education resources. Always prioritize your health and safety when considering any substance use.
References
- The “EMCDDA–Europol 2010 Annual Report” is a valuable resource in the field of drug research, offering insights and analysis. This document is made available by the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA). You can find the original report in PDF format, but please note that it is archived since March 14, 2012. The report’s release date is noted as October 10, 2011.
- In Dublin, a researcher named Andy delves into the world of Head Shop drugs. This work is part of a comprehensive study, with “Research on Head Shop drugs in Dublin: Part 2” as a focal point. The findings and details can be explored further on Drugs.ie, a source based in Dublin.
- The National Advisory Committee on Drugs (NACD) in Dublin conducted an informative study titled “An overview of new psychoactive substances and the outlets supplying them.” This research is available in PDF format and was carried out by Kelleher, Christie, Lalor, Fox, Bowden, and O’Donnel. The original document can be accessed, with an archive date of November 25, 2011.
- In a retrospective study published in August 2021, Niebel, Westendorf, Krumbiegel, Hartwig, Parr, and Tsokos examined the prevalence and concentrations of new designer stimulants, synthetic opioids, benzodiazepines, and hallucinogens in postmortem hair samples. Their findings can be found in “Drug Testing and Analysis,” Volume 14, Issue 1, spanning pages 110 to 121. The study’s DOI is 10.1002/dta.3150, and the PMID is 34435749.
- For another insightful study, also in 2021, Niebel, Pragst, Krumbiegel, and Hartwig explored the prevalence of cathinones and other new psychoactive substances. This time, the focus was on hair samples from parents and children within families with known or suspected parental abuse of conventional illegal drugs. The study was published in “Forensic Science International,” Volume 331, and is available under DOI 10.1016/j.forsciint.2021.111148. The PMID is 34923263, and the S2CID is 245098357.